Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results